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Management of Sepsis would greatly benefit from the incorporation of simple and informative new
biomarkers in clinical practice. Ideally, a sepsis biomarker should segregate infected from non-infected
patients, provide information about prognosis and organ-specific damage, and be accessible to most
healthcare services. The immature platelet fraction (IPF) and immature reticulocyte fraction (IRF) are new
analytical parameters of the complete blood count, that have been studied as biomarkers of several
inflammatory conditions. Recently, a study performed in critically-ill patients suggested that IPF could be a
more accurate sepsis biomarker thanC-reactive protein (CRP) and procalcitonin. In this retrospective study
we evaluated the performance of IPF and IRF as biomarkers of sepsis diagnosis and severity. 41 patients
admitted to two intensive care units were evaluated, 12 of which with severe sepsis or septic shock, and 11
with non-complicated sepsis. Significantly higher IPF levels were observed in patients with severe sepsis/
septic shock. IPF correlated with sepsis severity scores and presented the highest diagnostic accuracy for the
presence of sepsis of all studied clinical and laboratory parameters. No significant differences were observed
in IRF levels. Our results suggest that IPF levels could be used as a biomarker of sepsis diagnosis and severity.
I
n the last years, the frequency of sepsis is increasing at a rate of nearly 10% per year1, probably due to
improvements in life expectancy, and the more frequent use of immune suppressive agents and invasive
procedures. Despite increasing knowledge about its pathogenesis, mortality rates as high as 30% are still
observed, even with best supportive care1. Early diagnosis is one of the most important challenges in sepsis
management2, as delay in sepsis recognition increases sepsis-related mortality. Another important challenge is
the heterogeneous nature of sepsis, limiting the effectiveness of a ‘‘one-size-fits-all’’ treatment strategy for these
patients3. In this context, the discovery of biomarkers capable to identify patients at a higher risk of sepsis
complications, or prone to specific sepsis complications, is regarded as a highly relevant field of sepsis research4.
Currently, procalcitonin andC-reactive protein (CRP) figure among the best studied biomarkers for the diagnosis
and monitoring of sepsis5,6. Nonetheless, barriers such as limited access still preclude their systematic incorp-
oration into sepsis management protocols. Ideally, a sepsis biomarker should be able to: (i) segregate sepsis from
other causes of sterile inflammation (SIRS), (ii) allow some kind of risk stratification, and (iii) identify subgroups
of patients with specific sepsis complications, enabling target-specific treatments. In addition, an informative
biomarker, whose measurement did not depend on complex and high-cost equipments and reagents, would
certainly represent an important improvement in sepsis management.
Thrombocytopenia has been recognized as a poor prognostic factor in sepsis for decades based on robust
epidemiologic data7, and new insights into the cellular pathways of the immune response led to the recognition of
platelets as key elements in the host response to an infection8,9. New hematologic automated analyzers used for
evaluation of the complete blood count (CBC), generate a series of advanced analytical parameters that permit a
more detailed evaluation of circulating blood cells, including platelets10. Parameters such as the immature
reticulocyte fraction (IRF) and immature platelet fraction (IPF) provide a more precise evaluation of red blood
cell and platelet production, allowing near real-time estimation of erythro and thrombopoiesis11,12. Diagnostic
accuracy studies performed in the last years suggest that both IRF and IPF can provide clinically relevant
information about inflammatory activity and disease prognosis10,13,14. In the context of sepsis, a recent study
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conducted in critically-ill patients suggested that the IPF increases
before sepsis becomes clinically manifest, representing amore accur-
ate biomarker than procalcitonin and CRP15. The aim of our study
was to evaluate the performance of IRF and IPF as biomarkers of
sepsis development and sepsis severity.
Methods
Study design, patients and clinical data. This was a retrospective observational
cross-sectional study aimed to evaluate the association of IRF and IPF levels with the
diagnosis of SIRS (systemic inflammatory response syndrome), sepsis and with sepsis
severity markers. The study population consisted of all consecutive admissions to two
intensive care units (ICU) from a 400-bed academic hospital, occurring fromMonday
to Friday, during a 30-day period (May 2013). All descriptive data, consisting of
demographics, diagnosis, clinical and laboratory data, and sepsis severity scores were
obtained from the medical and laboratory records. The study was approved by the
local IRB, and was conducted in accordance with the Protocol of Helsinki. All data
was de-identified to protect patient confidentiality.
Sepsis definitions and severity scores. The diagnosis of SIRS, sepsis, severe sepsis,
and septic shock in these patients were registered in the medical records by the
attending physicians based on classical SIRS and sepsis criteria30. Similarly, clinical
severity scores were daily assessed by the intensive care staff using the sepsis-related
organ failure assessment (SOFA)31, and Acute Physiology and Chronic Health
Evaluation II (APACHEII)32. Sepsis severity scores were retrospectively checked by
one investigator, using clinical and laboratory data from the medical records.
Measurement of IPF and IRF. The IPF and IRF were obtained in an automated
hematology analyzer (Sysmex XE5000, Kobe, Japan). These parameters were
automatically measured when the first CBC after ICU admission was performed. All
IPF and IRF values used in this study were obtained within 24 hours from ICU
admission. IPF and IRF were measured in a dedicated reticulocyte/platelet channel of
the hematology analyzer by flow cytometry, using a proprietary fluorescent dye
containing polymethine and oxazine. This dye penetrates the cell membrane, staining
RNA in reticulocytes and in immature (or reticulated) platelets. By analyzing cell
volume and fluorescent intensity from these cells, a computer algorithm
discriminates (i) red blood cells from reticulocytes; (ii) low, medium and high
fluorescent reticulocyte populations; and (iii) platelets with higher RNA content,
referred to as immature platelets. The IPF correspond to the fraction (%) of immature
platelets from the total platelet population. The IRF corresponds to the fraction (%) of
medium and high fluorescence reticulocytes. A local reference ranges for both IPF
and IRF had been previously determined from samples of 178 healthy individuals,
using the same equipment and analytical protocols.
Statistical Analysis. Data are expressed as median, range, mean and standard
deviation. Continuous variables were compared using the Mann-Whitney test, and
categorical variables were compared with the Fisher’s exact test. Correlation
(Spearman’s rank correlation) analysis was performed between sepsis severity scores
andCBCparameters. Diagnostic accuracy was estimated using the ROCprocedure. A
p, 0.05 was considered significant. All analyses were performed using the GraphPad
Prism software (GraphPrism Software Inc. San Diego, California, USA).
Results
Study population. In total, 41 patients were admitted to both ICUs
during the study period. Of these, 23 patients presented criteria for
sepsis, and 14 were diagnosed with isolated SIRS. The remaining 4
patients did not present criteria for sepsis or SIRS (they were patients
admitted to the ICU for perioperative care). Of the 23 patients with
sepsis, 12 presented severe sepsis or septic shock at the time of
admission, and 11 had non-complicated sepsis. The median
APACHE-II and SOFA of these two subgroups at admission were
15 (range 6–37) and 6 (range 1–17), respectively. Other clinical and
demographic characteristics are shown in table 1.
IPF and IRF in patients with sepsis and SIRS. We first evaluated
whether either the IPF or the IRF could discriminate patients with
sepsis from patients with SIRS. As shown in figure 1, IPF was not able
to discriminate these two populations. In regard to the IRF, we
observed only a trend (P 5 0.052) towards lower values in patients
with SIRS (figure 1). Of note, our subgroup of SIRS patients consisted
mostly of individuals in the immediate post-operative phase ofmajor
surgeries, associated with significant bleeding. Since major bleeding,
a well-known stimulus for red blood cell and platelet production, can
potentially influence IPF and IRF levels, all subsequent analyses
considered only the subgroup of patients with sepsis.
IPF and IRF are higher in sepsis patients than in healthy
individuals. We next compared IPF and IRF values between
patients with sepsis and a population of healthy individuals, used
for the determination of our local reference range. As shown in
figure 2, despite similar platelet and absolute reticulocyte counts, a
Table 1 | Patient characteristics
Sepsis (n 5 11) Severe sepsis/ septic shock (n 5 12) P*
Sex (male:female ratio) 754 557 ns
Age (years) (median, range) 56 (22–85) 59 (38–52) ns
SOFA – admission (median,range) 3 (2–9) 10 (2–17) 0.01
APACHE-II – admission (median, range) 12 (6–27) 20 (12–37) ,0.001
SIRS criteria (mean 6 SD)
Temperature (uC) 37.0 6 0.8 37.1 6 0.9 ns
Heart rate (beats per minute) 107.5 6 18.8 113.5 6 15.9 ns
Breath rate (per minute) 27.8 6 14.9 22.7 6 9.6 ns
White blood cell count (*103/ml) 16.1 6 10.5 15.9 6 7.4 ns
Immature forms (%) 10.5 6 12.6 6.0 6 9.8 ns
Additional clinical and laboratory variables (mean 6 SD)
PaO2/FlO2 (mmHg) 296.0 6 115.8 235.6 6 132.3 ns
Platelet count (*109/l) 271 6 138 206 6 102 ns
Mean arterial pressure (mmHg) 97.1 6 29.7 102.1 6 11.1 ns
Urine output (l/day) 1.6 6 5.9 2.1 6 2.1 ns
Creatinine (mg/dl) 1.7 6 1.5 1.3 6 0.8 ns
Bilirrubin (mg/dl) 0.9 6 0.9 1.8 6 2.9 ns
C-reactive protein (mg/l) 11.6 6 8.0 11.6 6 7.5 ns
Lactate (mmol/l) 1.1 6 0.5 4.0 6 2.7 ,0.001
D-dimer(mg/ml) 3.1 6 1.8 3.0 6 1.5 ns
Prothrombin time (INR) 1.6 6 1.3 1.5 6 0.4 ns
aPTT ratio 1.1 6 0.3 1.2 6 0.3 ns
Advanced hematological parameters (mean 6 SD)
Immature platelet fraction (%) 3.6 6 2.6 6.2 6 3.0 0.03
Immature reticulocyte fraction (%) 12.6 6 6.0 20.6 6 15.4 ns
*D-dimer levels available for 17 patients. aPTT: activated partial thromboplastin time.
www.nature.com/scientificreports
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significant increase in both IRF and IPF could be observed in our
population (n 5 23) compared to healthy individuals (n 5 178).
IPF is associated with sepsis severity. In order to evaluate whether
IPF or IRF were associated with sepsis severity, patients with severe
sepsis or septic shock (‘‘severe sepsis’’ group; n5 12) were compared
with patients with non-complicated sepsis (‘‘sepsis’’ group; n 5 11).
When evaluated at the time of ICU admission, neither C-reactive
protein, nor platelet count were able segregate these two subgroups,
with only lactate presenting a significant difference between them
(Figure 3a–c). IRF values were also similar between these two sepsis
subgroups (figure 3d). In contrast, IPF was significantly higher in
patients with severe sepsis compared to non-complicated sepsis
patients (figure 4a). Similar findings were observed when patients
were stratified by the median SOFA score, with patients with a SOFA
$ 6 presented significantly higher IPF (IPF 5 6.2% vs. 2.9%; p 5
0.02) (figure 4b).
We also estimated the diagnostic accuracy of several clinical and
laboratory parameters evaluated in our patients, for the presence of
severe sepsis/septic shock. Within all laboratory parameters, IPF
yielded the highest area under the ROC curve (Table 2).
Finally, we investigated if IPF correlated with the SOFA severity
score. As previously demonstrated by several authors, a strong
inverse correlation between platelet count and the IPF was observed
(Rs 5 20.70; p , 0.001). No correlation between the SOFA score
with platelet count or C-reactive protein could be observed at the
time of ICU admission. In contrast, a significant correlation between
IPF and the SOFA score could be demonstrated (Rs 5 0.50; p 5
0.04).
Association of the IPF with other coagulation laboratory parameters.
A secondary objective of our study was to evaluate the association of
the IPF with other coagulation laboratory parameters, to explore
whether the increase in IPF could represent a marker of coagulation
activation during sepsis. No significant correlation could be demon-
strated between IPF and the prothrombin time or the APTT (available
for all patients with sepsis), nor between the IPF and D-dimer
(available in 17 patients with sepsis).
Discussion
Early recognition is a key goal of sepsismanagement protocols2, since
delayed antibiotic therapy increases morbidity and mortality rates of
septic shock by 7.6% per hour after the onset of hypotension, and
generates significant higher costs to the health care system16. For this
reason, the search for new biomarkers capable of predicting early
sepsis development, as well as the risk of sepsis complications,
remains one of the most active areas of sepsis research17.
In a recent study, De Blasi et al15 showed that the IPF was capable
to predict the development of sepsis up to 3 days before sepsis
become clinically manifest, with IPF values above 4.7% presenting
a specificity of 90.0% and a sensitivity of 56.2% for sepsis develop-
ment. IPF also showed to be the only variable correlated with the
development of sepsis15. In another study that evaluated the asso-
ciation between high IPF values and the presence of bloodstream
infections, Di Mario et al18 showed that the samples with positive
blood cultures had significantly highermean IPF values (4.86%) than
samples with negative blood cultures (1.79%). IPF and IRF are labor-
atory parameters derived from the CBC in automated hematological
analyzers available in most healthcare services19. As such, they could
Figure 1 | IPF and IRF in sepsis and SIRS. Box-plot showing similar
IPF and IRF values in patients with sepsis (n 5 23) and SIRS (n 5 14).
Mann-Whitney test.
Figure 2 | IPF and IRF in sepsis patients compared to healthy individuals.
Box-plot showing significantly increased values for IPF and IRF in
patients with sepsis (n 5 23) compared to healthy individuals (n 5 178).
Mann-Whitney test.
www.nature.com/scientificreports
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represent readily available and low-cost sepsis biomarkers, accessible
to several healthcare units.
In our study, IPF and IRF could not discriminate SIRS from sepsis,
in contrast to what has been suggested in a previous population of
critically-ill patients15. Our population of patients with SIRS con-
sisted of patients submitted to complex cardiac surgical procedures,
in the immediate post-operative phase. These procedures were assoc-
iated with extensive trauma, significant bleeding and exposure to
extracorporealmembrane oxygenation, all of which could have influ-
enced the kinetics of red blood cells and platelet production. Since the
IPF and IRF are very sensitive biomarkers of erythro- and thrombo-
poiesis11,12, this characteristic of our population may explain the
inability of the IPF to segregate SIRS from sepsis in our study. The
lower IRF levels observed in our SIRS patients compared to sepsis
could reflect the well-described negative impact of acute inflam-
mation on erythropoiesis20,21. Accordingly, IRF levels at the same
population increased sharply 7 days after ICU admission (data not
shown), suggesting that results obtained within 24 hours frommajor
surgeries might be influenced by erythropoietic response to trauma
and bleeding. Alternatively, the power of our study to detect a dif-
ference in IPF values between sepsis and SIRS might have been lower
than necessary. Whatever the reasons might be, critically-ill patients
in real-life settings will most certainly include surgical patients, and
future studies about the role of IPF as a biomarker of SIRS and sepsis
should try to enroll individuals submitted to major surgery, so that
results can be generalized to these patients.
On the other hand, when patients with non-complicated sepsis
were compared with patients with severe sepsis/septic shock, IPF and
lactate were the only significantly different clinical and laboratory
parameters. Neither platelet counts, C-reactive protein, nor any
other individual laboratory or clinical parameters, including IRF,
were different between these two populations at the time of ICU
admission. Moreover, within all laboratory parameters, the IPF
yielded the highest area under the ROC curve to discriminate severe
sepsis/septic shock fromnon-complicated sepsis. In addition, the IPF
also presented a strong correlation with sepsis severity scores such as
SOFA and APACHE-II. In this regard, our results confirm the
recently described association of the IPF with sepsis severity15 in
an independent population, supporting the potential of this simple
and straightforward CBC parameter as a biomarker of sepsis severity
at the time of ICU admission.
The mechanism behind the association of IPF with sepsis and
sepsis severity remains to be determined. We believe that higher
IPF could be part of the ongoing inflammatory response to sepsis,
in which platelets have been shown to play important roles9.
Accordingly, it has been demonstrated that platelets express many
types TLR receptors8, which are key regulators of the innate immune
response to pathogens. Activation of these receptors leads to the
release of IL-1b and formation of neutrophil extracellular traps
(NETs)8,22,23, which trap invading pathogens in infection sites.
Therefore, higher IPF values in patients with sepsis compared to
healthy individuals, as well as its association with sepsis severity
might reflect the formation and recruitment of newly formed plate-
lets, as part of a TLR-mediated mechanism triggered by infections.
Alternatively, higher IPF levels in sepsis, and especially in patients
with severe sepsis, might be a reflex of ongoing disseminated intra-
vascular coagulation (DIC), which results in compensatory platelet
production. In fact, IPF has been previously correlated with DIC
Figure 3 | Association of laboratory parameters with sepsis severity. Box-plot showing that neither C-reactive protein (a), platelet count (b), nor IRF
(d) presented significant differences between patients with severe sepsis or septic shock (‘‘severe sepsis’’ group; n 5 12), compared to non-complicated
sepsis (‘‘sepsis’’ group; n 5 11). As expected, lactate levels were higher in the former group (c). All values obtained at the time of ICU admission.
Mann-Whitney test.
www.nature.com/scientificreports
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scores in a cohort of critically-ill patients24. In our study, IPF did not
correlate with coagulation tests such as prothrombin time, aPTT and
D-dimer, but our study was not powered to draw any definite con-
clusion about this attractive mechanism of IPF increase during sep-
sis. Although additional studies are necessary to more precisely
understand the biological rationale behind the association of IPF
and sepsis, IPF should be considered a type 0 biomarker, according
to a previously published classification25,26. Type 0 biomarkers
include markers of the natural history of a disease and correlate
longitudinally with known clinical indices such as symptoms over
the full range of disease states.
Validation of a sepsis biomarker is a stepwise process that must
necessarily involve its evaluation in different populations, and in
conditions that mimic the so-called ‘‘real-life’’ conditions27.
Compared to previous reports, our population presents some char-
acteristics that more closely resemble a population in which a sepsis
biomarker would be useful such as the inclusion of thrombocyto-
penic patients, which were excluded from both previous studies that
evaluated the IPF in this context15,18. Examples of discrepancies
between preliminary and validation studies despite adequate study
design are available for several sepsis biomarkers28,29, so that con-
firmatory studies should be regarded as a fundamental part of the
initial effort to validate a biomarker. In this context, our observation
that IPF is associated with sepsis severity in an independent popu-
lation adds strength to the recent demonstration of its potential as a
sepsis biomarker.
Our study has important limitations that need to be taken into
consideration. First, the relative small number of patients may have
limited the statistical power to detect a difference in IPF values
between sepsis and SIRS. Second, the retrospective nature of our
study precluded us to calculate a DIC score, which relies on fibrino-
gen levels, in our patients. D-dimer levels were available for a sub-
group of patients, but a formal evaluation of the association of IPF
with DIC was not possible in our study. On the other hand, the
unbiased patient selection from two independent ICUs, the adequate
characterization of sepsis diagnosis and severity scores, and the
inclusion of major surgery and thrombocytopenic patients more
closely resembling a real-life scenario in which a sepsis biomarker
would be used are important strengths of our study.
Conclusions
IPF values obtained within 24 hours from ICU admission are higher
in patients with sepsis compared to healthy individuals, and correlate
with sepsis severity scores.Measurement of the IPF is simple, and can
be done as part of a CBC of some automated hematology analyzers.
Therefore, our results confirm and extend a recent report of IPF as an
informative sepsis biomarker, in an independent and clinically rep-
resentative population. Larger studies are warranted to define how
this readily accessible parameter could be incorporated in sepsis
management protocols.
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